0001209191-19-030512.txt : 20190516
0001209191-19-030512.hdr.sgml : 20190516
20190516172541
ACCESSION NUMBER: 0001209191-19-030512
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190514
FILED AS OF DATE: 20190516
DATE AS OF CHANGE: 20190516
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hagan Joseph P
CENTRAL INDEX KEY: 0001465278
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35670
FILM NUMBER: 19833407
MAIL ADDRESS:
STREET 1: 3344 N. TORREY PINES COURT, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Regulus Therapeutics Inc.
CENTRAL INDEX KEY: 0001505512
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 264738379
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-202-6300
MAIL ADDRESS:
STREET 1: 10628 SCIENCE CENTER DRIVE
STREET 2: SUITE 100
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-14
0
0001505512
Regulus Therapeutics Inc.
RGLS
0001465278
Hagan Joseph P
C/O REGULUS THERAPEUTICS INC.
10628 SCIENCE CENTER DR., #100
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2019-05-14
4
A
0
188385
0.00
A
307519
D
Common Stock
2019-05-16
4
S
0
39352
1.2189
D
268167
D
Stock Option (Right to Buy)
0.95
2019-05-14
4
A
0
10000
0.00
A
2019-05-14
2029-02-04
Common Stock
10000
10000
D
On November 11, 2018, the reporting person was granted Restricted Stock Units in the Company's tender offer. The RSUs vest only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the RSUs. Upon achievement of the milestone, 50% of the RSU subject to the milestone immediately vest, with the remaining RSUs vesting quarterly in the 24 months following the vesting commencement date.
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person on 5/14/2019. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.1946 to $1.2210 inclusive. The reporting person undertakes to provide to RGLS, any security holder of RGLS, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote to this Form 4.
On February 5, 2019, the reporting person was granted an option to purchase the number of shares of common stock set forth in Box 5. The option vests only upon the achievement of a performance-based milestone. The performance criteria were met, resulting in vesting of the option. Upon achievement of the milestone, 50% of the options subject to the milestone immediately vest, with the remaining options vesting in 24 equal monthly installments following the vesting commencement date.
Christopher Aker, Attorney in Fact
2019-05-16